Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Ms. Li Fangyu, in the future development of the company through her acquisition of 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] Group 1: Share Acquisition - Ms. Li Fangyu increased her stake in the company by acquiring 41,500 ordinary shares through LIFY Management Holdings Limited in the open market [1] - The company repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Group 2: Management Confidence - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board expresses confidence that the share repurchase demonstrates management's strong belief in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]
美丽田园医疗健康获非执行董事李方雨增持4.15万股